Compass Therapeutics, Inc.

NasdaqCM:CMPX Stock Report

Market Cap: US$152.7m

Compass Therapeutics Future Growth

Future criteria checks 2/6

Compass Therapeutics is forecast to grow earnings and revenue by 50.7% and 66.1% per annum respectively while EPS is expected to grow by 52.5% per annum.

Key information

50.7%

Earnings growth rate

52.5%

EPS growth rate

Biotechs earnings growth24.6%
Revenue growth rate66.1%
Future return on equityn/a
Analyst coverage

Good

Last updated03 Jun 2024

Recent future growth updates

Recent updates

We Think Compass Therapeutics (NASDAQ:CMPX) Can Afford To Drive Business Growth

Jun 05
We Think Compass Therapeutics (NASDAQ:CMPX) Can Afford To Drive Business Growth

We're Hopeful That Compass Therapeutics (NASDAQ:CMPX) Will Use Its Cash Wisely

Feb 13
We're Hopeful That Compass Therapeutics (NASDAQ:CMPX) Will Use Its Cash Wisely

Companies Like Compass Therapeutics (NASDAQ:CMPX) Are In A Position To Invest In Growth

Sep 20
Companies Like Compass Therapeutics (NASDAQ:CMPX) Are In A Position To Invest In Growth

Compass Therapeutics, Merck ink collaboration deal for early-stage cancer trial

Oct 11

Earnings and Revenue Growth Forecasts

NasdaqCM:CMPX - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202669-45N/A-597
12/31/20255-71N/A-557
12/31/2024N/A-55N/A-487
3/31/2024N/A-45-42-42N/A
12/31/2023N/A-42-41-41N/A
9/30/2023N/A-41-39-39N/A
6/30/2023N/A-43-44-44N/A
3/31/2023N/A-40-38-38N/A
12/31/2022N/A-39-34-34N/A
9/30/2022N/A-41-29-28N/A
6/30/2022N/A-35-22-21N/A
3/31/2022N/A-82-24-22N/A
12/31/2021N/A-82-22-20N/A
9/30/2021N/A-78-23-22N/A
6/30/2021N/A-81-26-25N/A
3/31/2021N/A-31-25-25N/A
12/31/2020N/A-29-27-27N/A
9/30/2020N/A-28-26-26N/A
6/30/2020N/A-27-26-25N/A
3/31/2020N/A-30-29-29N/A
12/31/2019N/A-35-32-32N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: CMPX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: CMPX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: CMPX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: CMPX's revenue (66.1% per year) is forecast to grow faster than the US market (8.6% per year).

High Growth Revenue: CMPX's revenue (66.1% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if CMPX's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.